Evidence map›Paper›PMID 42351313›Full record

ArticleActa neuropathologica communications2026

A rare missense variant impacting NEK1 kinase function is associated with ALS.

David Brenner, Anna Ponomarenko, Iris Petrut, Sofia Beyrle, Matilde Contardo, Isabel Loss, Constantin Radke, Jonas Frank, Eleni Zimmer, Matthias Schlesner and 21 more

Erratum issuedAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors.

David Brenner *Department of Neurology, University Hospital Ulm, 89081, Ulm, Germany. david.brenner@uni-ulm.de.
Anna Ponomarenko *Institute of Anatomy and Cell Biology, Ulm University School of Medicine, 89081, Ulm, Germany.
Iris PetrutInstitute of Anatomy and Cell Biology, Ulm University School of Medicine, 89081, Ulm, Germany.
Sofia BeyrleInstitute of Anatomy and Cell Biology, Ulm University School of Medicine, 89081, Ulm, Germany.
Matilde ContardoDepartment of Neurosciences, Laboratory of Neurobiology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, 3000, Leuven, Belgium.
Isabel LossDepartment of Neurology, University Hospital Ulm, 89081, Ulm, Germany.
Constantin RadkeInstitute of Neuropathology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Jonas FrankBiomedical Informatics, Data Mining and Data Analytics, University of Augsburg, 86159, Augsburg, Germany.
Eleni ZimmerInstitute of Molecular Oncology and Stem Cell Biology (IMOS), Ulm University Hospital, 89081, Ulm, Germany.
Matthias SchlesnerBiomedical Informatics, Data Mining and Data Analytics, University of Augsburg, 86159, Augsburg, Germany.
Pascal AchenbachInstitute of Neuropathology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Wendy ScheveneelsDepartment of Neurosciences, Laboratory of Neurobiology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, 3000, Leuven, Belgium.
Amr AlyInstitute of Anatomy and Cell Biology, Ulm University School of Medicine, 89081, Ulm, Germany.
Hülya NazlicanDepartment of Neurology, Centre for ALS and Other Motor Neuron Disorders, Alfried Krupp Krankenhaus Rüttenscheid, 45131, Essen, Germany.
Jasper Hesebeck-BrinkmannDepartment of Neurology, University Hospital Ulm, 89081, Ulm, Germany.
Patrick OecklDepartment of Neurology, University Hospital Ulm, 89081, Ulm, Germany.
Kathrin MüllerInstitute of Human Genetics, Ulm University and Ulm University Medical Center, Ulm, Germany.
Reiner SiebertCenter for Rare Diseases (ZSE) Ulm, Ulm University Hospital Center for Rare Diseases, 89081, Ulm, Germany.
Tobias BöckersGerman Center for Neurodegenerative Diseases (DZNE), Ulm site, 89081, Ulm, Germany.
Kristel van EijkDepartment of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Jan VeldinkDepartment of Neurology, Brain Centre Rudolf Magnus, University Medical Centre Utrecht, Utrecht University, 3584 CG, Utrecht, The Netherlands.
Alexander KlegerCenter for Rare Diseases (ZSE) Ulm, Ulm University Hospital Center for Rare Diseases, 89081, Ulm, Germany.
Medhanie MulawUnit for Single-Cell Genomics, Medical Faculty, Ulm University, 89081, Ulm, Germany.
Peter M AndersenDepartment of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Karin ForsbergDepartment of Clinical Sciences, Neurosciences, Umeå University, Umeå, Sweden.
Jochen H WeishauptDepartment of Neurology, University Hospital Ulm, 89081, Ulm, Germany.
Seyed Babak LoghmaniDepartment of Neurology, University Hospital Ulm, 89081, Ulm, Germany.
Thorsten GrehlDepartment of Neurology, Centre for ALS and Other Motor Neuron Disorders, Alfried Krupp Krankenhaus Rüttenscheid, 45131, Essen, Germany.
Philip van DammeDepartment of Neurosciences, Laboratory of Neurobiology and Leuven Brain Institute (LBI), KU Leuven-University of Leuven, 3000, Leuven, Belgium.
Joachim WeisInstitute of Neuropathology, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Alberto CataneseGerman Center for Neurodegenerative Diseases (DZNE), Ulm site, 89081, Ulm, Germany. acatanese@ukaachen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterozygous truncating loss-of-function (LoF) variants in NEK1 are a known cause of amyotrophic lateral sclerosis (ALS). NEK1 encodes the pleiotropic serine/threonine kinase NIMA-related kinase 1, and prior in vitro studies have implicated kinase dysfunction as the principal pathogenic mechanism underlying NEK1-associated ALS. However, bona fide pathogenic missense variants causally linked to ALS have not previously been reported, leaving this hypothesis unconfirmed. Here, we identify a rare NEK1 missense variant, p.N598S, that co-segregates with disease in a familial ALS pedigree and is enriched in European ALS cohorts. This variant exhibits normal protein expression levels, indicating a functional rather than quantitative defect. Using isogenic human motor neurons, we directly compared the effects of p.N598S with those of the ALS-associated truncating variant p.R812* to delineate disease mechanisms. The p.N598S variant induced pathological phenotypes consistent with NEK1 haploinsufficiency, including increased susceptibility to DNA damage, increased apoptosis, ciliary dysmorphia, and nucleocytoplasmic translocation of TDP-43. Importantly, p.N598S impaired NEK1 kinase activity, and pharmacological inhibition of NEK1 recapitulated the cellular phenotypes observed in both p.N598S- and p.R812*-mutant motor neurons. Collectively, these findings provide strong genetic and functional evidence for a disease-causing role of NEK1 kinase disruption in NEK1-ALS. Our findings provide immediate diagnostic and therapeutic implications, particularly for the functional interpretation of missense variants of uncertain significance and the development of targeted treatment strategies.

Indexed as

Amyotrophic Lateral SclerosisMutation, MissenseNIMA-Related Kinase 1AnimalsFemaleHumansMaleMotor NeuronsPedigreeNEK1 protein, humanNIMA-Related Kinase 1ALSAutophagyGeneticsKinaseMissense variantNEK1TDP-43 pathology

Identifiers

PMID42351313
PMCPMC13307424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.